The UK is sticking with its decision to increase the rebate that pharmaceutical companies pay on sales of branded medicines to the National Health Service under the statutory pricing scheme, the Department of Health and Social Care has announced.
Following a consultation launched last year in which industry respondents expressed opposition to the increase, the rebate for 2023 is to rise from 24.4% to 27.5% to ensure the statutory scheme maintains “broad commercial equivalence” with the voluntary pricing scheme for branded medicines, the VPAS
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?